Veronica Mollica
Overview
Explore the profile of Veronica Mollica including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
188
Citations
2162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Danielli L, Tassinari E, Marchetti A, Rosellini M, Mollica V, Cheng L, et al.
Expert Rev Anticancer Ther
. 2025 Mar;
PMID: 40089934
Introduction: Prostate cancer represents a significant oncological challenge, with its natural history predominantly driven by androgen receptor (AR) signaling. The pivotal role of this pathway underscores the rationale for targeting...
2.
Hannan R, Mollica V, Palumbo C, Erdem S
Eur Urol Oncol
. 2025 Mar;
PMID: 40089404
No abstract available.
3.
Rosellini M, Tassinari E, Danielli L, Marchetti A, Ricci C, Santoni M, et al.
Expert Rev Mol Diagn
. 2025 Mar;
:1-4.
PMID: 40066646
No abstract available.
4.
Marandino L, Mollica V, Campi R
Curr Opin Urol
. 2025 Feb;
PMID: 39995165
Purpose Of Review: Advancements in immune-oncology treatments and metastasis-directed therapy (MDT) techniques have significantly transformed treatment paradigms for patients with oligometastatic clear cell renal cell carcinoma (ccRCC). Within this evolving...
5.
Ricci C, Melotti S, Di Sciascio L, Ambrosi F, Grillini M, Mollica V, et al.
Virchows Arch
. 2025 Feb;
PMID: 39992438
Sarcomatoid yolk sac tumor postpubertal-type (YSTpt) is a rare phenotype of germ cell tumor that occurs mostly after chemotherapy. Its diagnosis is clinically relevant but challenging, due to its somewhat...
6.
Marchetti A, Mollica V, Brocchi S, Cattabrigra A, Tassinari E, Rosellini M, et al.
Expert Rev Mol Diagn
. 2025 Feb;
:1-3.
PMID: 39949118
No abstract available.
7.
Giudice G, Maffezzoli M, Testi I, Acunzo A, Agnetti V, Tuttobene P, et al.
Expert Rev Anticancer Ther
. 2025 Feb;
PMID: 39930832
Introduction: metastasis-directed treatment (MDT) is progressively expanding its scope in the treatment of metastatic renal cell carcinoma (mRCC), finding application both in cases of oligometastatic disease, whether synchronous or metachronous,...
8.
Coriano M, Lazzarin A, Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, et al.
Immunotherapy
. 2025 Jan;
17(1):25-35.
PMID: 39829377
Background: The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus...
9.
Santoni M, Mollica V, Rizzo A, Massari F
Cancer Treat Rev
. 2025 Jan;
133:102881.
PMID: 39799795
Immune-based combinations are the cornerstone of the first-line treatment of metastatic renal cell carcinoma patients, leading to outstanding outcomes. Nevertheless, primary resistance and disease progression is a critical clinical challenge....
10.
Rizzo A, Marques Monteiro F, Mollica V, Brunetti O, Vitale E, Sciacovelli A, et al.
Clin Exp Metastasis
. 2024 Dec;
42(1):9.
PMID: 39739072
Immune-based combinations have significantly improved the treatment of metastatic renal cell carcinoma (mRCC); however, immunotherapy has reported varying degrees of efficacy across different metastatic sites, with liver and bone metastases...